MedTrace Logo

RX-5902 Treatment of Subjects With Triple Negative Breast Cancer

NCT02003092 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-01-06

No results posted yet for this study

Summary

The purpose of this Phase 2 portion of the study is to use the dose and schedule of RX-5902 identified in the phase 1 to treat subjects with triple negative breast cancer.

Conditions

Interventions

DRUG

RX-5902

escalating doses (mg)

Sponsors & Collaborators

  • Rexahn Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Ely Benaim, MD · Rexahn Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2019-10-31
Completion
2019-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02003092 on ClinicalTrials.gov